secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004151
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma reaffirms FY2022 revenue guidance at J.P. Morgan conference
-----------------------------------------------------------------------

- Company expects to meet previously announced total, neuroscience and oncology revenue guidance for FY2022.
- Presentation includes corporate overview and financial update; no change to existing guidance ranges.
- No specific revenue or earnings figures disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312523004151/0001193125-23-004151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312523004151/d442750d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer